QPPV.COM KNOWLEDGE ASSESSMENT

Eculizumab Biosimilar: C5 Complement Blockade, Biosimilarity and Pharmacovigilance

Test your understanding of the concepts covered by Eculizumab Biosimilar: C5 Complement Blockade, Biosimilarity and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which medication error would be particularly important to identify in a pharmacovigilance narrative for eculizumab?

Confusion between complement inhibitors or an incorrect dosing interval that results in omitted loading or maintenance exposure A patient receiving routine counselling about infection symptoms A laboratory result being recorded with both its value and collection date A documented product batch number accompanying an infusion record

Question 2 of 10 Which evidence most directly supports assessment of disease activity in a patient treated for aHUS?

Only the patient's reported fatigue score Platelet count, LDH, haemoglobin, schistocytes, haptoglobin, creatinine and organ outcomes tracked over time The number of prior infusion reactions to unrelated medicines The product brand name without clinical or laboratory information

Question 3 of 10 What is the most important pharmacovigilance concern when eculizumab treatment is interrupted or discontinued?

The active substance becomes permanently ineffective after one missed dose Loss of terminal-complement blockade may allow recurrence of PNH haemolysis or aHUS thrombotic microangiopathy Treatment interruption eliminates all infection risk immediately Discontinuation affects only infusion tolerability and not disease activity

Question 4 of 10 Why does terminal-complement blockade create both therapeutic benefit and a major infectious risk?

The same inhibition that limits complement-mediated tissue injury also weakens terminal-complement defence against encapsulated bacteria, particularly Neisseria meningitidis C5 blockade suppresses bone-marrow production of neutrophils and therefore causes all bacterial infections The antibody neutralises bacterial toxins but induces viral reactivation The therapeutic effect depends on broad immunosuppression unrelated to complement function

Question 5 of 10 Why should a report of suspected aHUS treatment failure include information about the diagnostic basis and alternative causes of thrombotic microangiopathy?

Because eculizumab is only effective when the underlying process is complement-mediated, and several other TMA causes require different interpretation and management Because aHUS can only be diagnosed after a patient has received two different biosimilars Because complement inhibitors are contraindicated whenever infection or pregnancy is present Because platelet count is not relevant to aHUS assessment

Question 6 of 10 Why should pharmacovigilance analyses use both active-substance-level and brand-level views?

Active-substance aggregation assesses class risks, while brand-level analysis supports traceability and detection of potential product-specific patterns Brand-level analysis is sufficient because mechanism never matters Active-substance aggregation should always replace product identification The two analytical levels provide identical information and therefore either one is unnecessary

Question 7 of 10 Which information is most important when evaluating a suspected breakthrough event after a transition between eculizumab products?

The last reference-product dose, first biosimilar dose, any gap, infusion schedule and disease-marker trajectory Only the patient's country of birth Only whether the patient preferred the reference brand The number of products in the company's global portfolio

Question 8 of 10 Why should disseminated gonococcal infection also be considered in the safety surveillance of eculizumab?

It is an example of another Neisseria infection that may be facilitated by impaired terminal-complement defence It is the only infection prevented by meningococcal vaccination It demonstrates that eculizumab directly causes sexually transmitted infections It is unrelated to complement and therefore should be excluded from surveillance

Question 9 of 10 What is the best reason to document patient education and alert materials in a meningococcal infection case?

They help assess whether required risk-minimisation measures were implemented and may explain recognition or response to a rapidly progressive infection They determine whether the biosimilar has the same amino-acid sequence as the reference product They replace the need for microbiological confirmation They prove that any subsequent infection was unrelated to treatment

Question 10 of 10 Which statement best explains why authorised indications should not be assumed to be identical across all eculizumab biosimilar labels and jurisdictions?

Biosimilar authorisation and indication extrapolation are scientific and regulatory conclusions that depend on the applicable evidence and legal framework All biosimilars are restricted to indications that were not approved for the reference product Indications are determined solely by the product's brand name A biosimilar can never be authorised for more than one disease

Eculizumab Biosimilar: C5 Complement Blockade, Biosimilarity and Pharmacovigilance

Cookie Settings